ByTrending Posts
Will Veeva and Amgen’s $50 Billion Industry Push…
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive…
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of…
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s…
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin…
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Roche’s $700M Genentech Facility Drive Its $50B…
Key Highlights Strategic Expansion into US ManufacturingGenentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art…
Can Novartis and BioArctic’s $802M Alliance Unlock the…
Key Highlights Strategic Collaboration Targets Neurodegenerative DiseasesNovartis has entered into a research partnership with Sweden’s BioArctic, committing $30M…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock…
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
Could Halda Therapeutics and VantAI’s $1B AI Alliance…
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
Trending Posts
Latest Stories
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data…
Is Merck and Nvidia’s KERMT Model the Breakthrough That Finally Makes AI-Native Drug Discovery Faster, Greener, and More Predictive?
Key Highlights / Executive Takeaways: • Merck and Nvidia introduce KERMT, a next-generation small-molecule AI…
Will LabGenius Therapeutics and Sanofi’s Second AI-Powered Alliance Accelerate the Next Wave of Antibody and NANOBODY® Innovation in Inflammatory Diseases?
Key Highlights / Executive Takeaways: • Expanded collaboration deepens trust between LabGenius Therapeutics and Sanofi,…
Can Phare Bio and Basilea’s AI-Driven Alliance Redefine Antibiotic Discovery and Change the Fight Against Drug-Resistant Infections Worldwide?
Executive Takeaways: • First-of-its-kind partnership aligns AI-driven antibiotic design directly with patient-centric target product profiles,…
Gallery
